CVM 241220 2.00P (CVM241220P2000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Nov 29 09:30 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Stock_Drift

Nov 26 04:28

Premarket Ticks. 5:27am 11/26

$VSee Health (VSEE.US)$ $CEL-SCI (CVM.US)$ $SmartKem (SMTK.US)$ $Volato Group (SOAR.US)$ $Onconetix (ONCO.US)$ $Fusion Fuel Green (HTOO.US)$ $SEALSQ Corp (LAES.US)$ $Semtech (SMTC.US)$ $HA Sustainable Infrastructure (HASI.US)$ $Spectral AI (MDAI.US)$ $T Stamp (IDAI.US)$ $ZenaTech (ZENA.US)$ $Poseida Therapeutics (PSTX.US)$

Trytosaveabit

Nov 7 07:17

News

$CEL-SCI (CVM.US)$ U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
2 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
• Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study
• Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of 73% vs. 45% in the control group in the...

Jaguar8

Nov 7 07:15

NEWS

$CEL-SCI (CVM.US)$
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CEL-SCI (NYSE: CVM) announced FDA agreement on using PD-L1 biomarker for patient selection in its upcoming Multikine Registration Study for head and neck cancer, starting Q1 2025. The study will focus on patients with low PD-L1 tumor expression, following promising results from a previous Phase 3 study where patients showed 73% v...

Jaguar8

Oct 22 08:30

NEWS

$CEL-SCI (CVM.US)$
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Trytosaveabit

Oct 1 05:05

Update

$CEL-SCI (CVM.US)$ CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
4 MINUTES AGO, 6:00 AM EDT
VIA BUSINESSWIRE
As a clinical research organization (CRO) Ergomed has a strong track record with CEL-SCI in fast enrolment and high quality study delivery
CEL-SCI Corporation (NYSE:CVM) today announced its renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration (FDA) confirm...